Kane Biotech Inc (TSE:KNE)
:KNE
Want to see TSE:KNE full AI Analyst Report?
KNE Stock Chart & Stats
C$0.03
<C$0.01(4.76%)
At close: 4:00 PM EST
C$0.03
<C$0.01(4.76%)
Day’s Range― - ―
52-Week RangeC$0.03 - C$0.07
Previous CloseN/A
Volume199.87K
Average Volume (3M)112.95K
Market Cap
C$6.00M
Enterprise ValueC$7.77M
Total Cash (Recent Filing)C$901.70K
Total Debt (Recent Filing)C$2.30M
Price to Earnings (P/E)―
Beta0.61
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding181,856,570
10 Day Avg. Volume120,057
30 Day Avg. Volume112,955
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)-8.69
Price to Sales (P/S)15.17
P/FCF Ratio-1.99
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary Anti‑biofilm PlatformKane's core anti-biofilm technology targets a structural cause of persistent infections and contamination. That platform addresses multiple end-markets (wound care, animal health, industrial), creating durable IP-led differentiation and licensing potential that can scale without proportional manufacturing capex.
Multiple Monetization ChannelsA mix of product sales, licensing/royalties and partner collaborations provides diversified revenue paths. Licensing and royalty streams can offer recurring, scalable revenue with lower incremental costs, helping long-term margin improvement if adoption and partner deals progress.
Declining Reported DebtMaterial debt reduction versus 2023 eases near-term leverage pressure and refinancing risk. While equity remains negative, lower debt improves capital structure durability and gives more runway for R&D/commercial execution versus a higher-leverage baseline.
Bears Say
Persistent Net LossesSustained net losses and a negative gross profit point to weak unit economics and difficulty converting R&D into profitable products. Unless gross margins recover or scale offsets fixed costs, losses will continue to erode cash and restrict reinvestment in commercialization.
Negative Shareholders' EquityPersistently negative shareholders' equity is a structural balance-sheet weakness that limits financial flexibility. It raises creditor scrutiny, complicates debt/asset financing, and increases the likelihood of dilutive equity raises, impairing long-term stability and strategic options.
Chronic Cash BurnOngoing negative operating and free cash flow indicates the business depends on external funding to sustain operations. Even with modest improvement in 2025, repeated cash burn elevates financing risk, potential dilution, and constrains consistent investment in commercialization and R&D.
KNE FAQ
What was Kane Biotech Inc’s price range in the past 12 months?
Kane Biotech Inc lowest stock price was C$0.03 and its highest was C$0.07 in the past 12 months.
What is Kane Biotech Inc’s market cap?
Kane Biotech Inc’s market cap is C$6.00M.
When is Kane Biotech Inc’s upcoming earnings report date?
Kane Biotech Inc’s upcoming earnings report date is Aug 27, 2026 which is in 92 days.
How were Kane Biotech Inc’s earnings last quarter?
Currently, no data Available
Is Kane Biotech Inc overvalued?
According to Wall Street analysts Kane Biotech Inc’s price is currently Overvalued.
Does Kane Biotech Inc pay dividends?
Kane Biotech Inc does not currently pay dividends.
What is Kane Biotech Inc’s EPS estimate?
Kane Biotech Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Kane Biotech Inc have?
Kane Biotech Inc has 181,856,570 shares outstanding.
What happened to Kane Biotech Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Kane Biotech Inc?
Currently, no hedge funds are holding shares in TSE:KNE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Kane Biotech Inc
Kane Biotech Inc., a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops pet oral care products under the StrixNB and bluestem brands; animal and human wound care solutions under the DispersinB name; shampoos for dogs, cats, and horses under the Alosera name; and medical device coatings under the Aledex name. It also offers scalp care products under the DermaKB brand name, wound care products under the Coactiv+ brand name, as well as other products under the goldstem, silkstem, and DermaKB Biofilm brand names. Kane Biotech Inc. was incorporated in 2001 and is based in Winnipeg, Canada.
Technical Analysis
Aptose Biosciences
―
XORTX Therapeutics Inc
―
Quest Pharmatech
―
BioVaxys Technology
―
Doseology Sciences
―
Options Prices
Currently, No data available
---